Inactivated influenza vaccines (IIVs) lack broad efficacy. Cellular immunity to a conserved internal antigen， the nucleoprotein (NP)， has been correlated to protection against pandemic and seasonal influenza and thus could have the potential to broaden vaccine efficacy. We developed OVX836， a recombinant protein vaccine based on an oligomerized NP， which shows increased uptake by dendritic cells and immunogenicity compared with NP. Intramuscular immunization in mice with OVX836 induced strong NP-specific CD4+ and CD8+ T-cell systemic responses and established CD8+ tissue memory T cells in the lung parenchyma. Strikingly， OVX836 protected mice against viral challenge with three different influenza A subtypes， isolated several decades apart and induced a reduction in viral load. When co-administered with IIV， OVX836 was even more effective in reducing lung viral load.